SCHEMBL5225161

SCHEMBL5225161

O=C(O)c1cc2c(cn1)sc1ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 2/20 0.64
GABRD O14764 2/20 0.64
GABRA1 P14867 2/20 0.64
GABRB1 P18505 2/20 0.64
GABRG2 P18507 2/20 0.64
GABRB3 P28472 2/20 0.64
GABRA5 P31644 2/20 0.64
GABRA3 P34903 2/20 0.64
GABRA2 P47869 2/20 0.64
GABRB2 P47870 2/20 0.64
GABRA4 P48169 2/20 0.64
GABRE P78334 2/20 0.64
GABRA6 Q16445 2/20 0.64
GABRG1 Q8N1C3 2/20 0.64
GABRG3 Q99928 2/20 0.64
GABRQ Q9UN88 2/20 0.64
KMT2A Q03164 1/20 0.55
CYP1A2 P05177 1/20 0.46
GPR3 P46089 1/20 0.45
PTPN7 P35236 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL844422 0.87 GABRP (0.51) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5226233 0.82 GABRP (0.74) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7011557 0.79 GABRA1 (1.00) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL7017306 0.77 GABRP (0.56) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL444345 0.73 GPR3 (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5918007 0.73 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL441700 0.73 GPR3 (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL30839928 0.73 CYP1A2 (0.67) CYP1A2GPR3PTPN7DUSP3PTPN12
SCHEMBL16919880 0.73 GABRP (0.55) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL3111619 0.73 CYP1A2 (0.67) CYP1A2GPR3PTPN7DUSP3PTPN12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1425286-B1 SUBSTITUTED 7-AZA-[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES PHARMACIA & UPJOHN CO LLC (US) 2007-02-28 EP disclosed
US-7067515-B2 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease PFIZER INC. (US) 2006-06-27 US disclosed
EP-1425286-A1 SUBSTITUTED 7-AZA[2.2.1]BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES PHARMACIA & UPJOHN COMPANY (US) 2004-06-09 EP disclosed
EP-1406901-A1 QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-04-14 EP disclosed
US-20030105089-A1 Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-06-05 US disclosed
WO-2003022856-A1 SUBSTITUTED 7-AZA[2.2.1] BICYCLOHEPTANES FOR THE TREATMENT OF DISEASES PHARMACIA & UPJOHN COMPANY (US) 2003-03-20 WO disclosed
US-20030045540-A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-03-06 US disclosed
WO-2002100857-A1 QUINUCLIDINES-SUBSTITUTED-MULTI-CYCLIC-HETEROARYLS FOR THE TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105089-A1 Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease CHRNA7, CHRNA1, CHRNA6 GABRP 836/4885GABRD 266/4885GABRA1 151/4885
US-20030045540-A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease NQO2, SLC10A1, CYP7A1 GABRP 2938/4885GABRD 2498/4885GABRA1 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.